Clinical Scorecard: FDA Alignment Boosts Wet AMD Treatment Path
At a Glance
| Category | Detail |
|---|---|
| Condition | Wet Age-Related Macular Degeneration (AMD) |
| Key Mechanisms | AXPAXLI is a bioresorbable intravitreal hydrogel incorporating axitinib, a tyrosine kinase inhibitor with anti-angiogenic properties. |
| Target Population | Patients with wet AMD and diabetic retinal disease. |
| Care Setting | Clinical trials and regulatory submission processes. |
Key Highlights
- Ocular Therapeutix plans to submit a New Drug Application for AXPAXLI in Q4 2026.
- Submission based on Phase 3 SOL-1 efficacy and interim SOL-R safety data.
- AXPAXLI could potentially reach patients in 2027 if approved.
- A new key secondary endpoint will evaluate AXPAXLI against aflibercept at Week 96.
- SOL-R trial will remain masked through Week 96.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with wet AMD and diabetic retinal disease.
AXPAXLI shows unmatched durability and sustained disease control.
Clinical Best Practices
- Engage with regulatory bodies early in the drug development process.
- Utilize robust clinical trial data to support NDA submissions.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
